tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

INZY

Inozyme Pharma Requests Nasdaq Delisting Post-Acquisition
Company AnnouncementsInozyme Pharma Requests Nasdaq Delisting Post-Acquisition
25d ago
8K
INZY
Inozyme Pharma Reports Increased Loss Amid Strategic Focus
PremiumCompany Announcements
Inozyme Pharma Reports Increased Loss Amid Strategic Focus
2M ago
INZY
Inozyme Pharma Approves Executive Bonuses Amid Merger
PremiumCompany Announcements
Inozyme Pharma Approves Executive Bonuses Amid Merger
2M ago
8K
INZY
Biotech Alert: Searches spiking for these stocks today
PremiumThe Fly
Biotech Alert: Searches spiking for these stocks today
2M ago
ACAD
AFMD
Inozyme downgraded to Hold from Buy at TD Cowen
PremiumThe Fly
Inozyme downgraded to Hold from Buy at TD Cowen
2M ago
INZY
Inozyme Pharma’s Strategic Acquisition by Biomarin: Analyst Holds Rating Amid Favorable Shareholder Outcome and Strategic Alignment
PremiumRatingsInozyme Pharma’s Strategic Acquisition by Biomarin: Analyst Holds Rating Amid Favorable Shareholder Outcome and Strategic Alignment
2M ago
INZY
Inozyme downgraded to Neutral from Overweight at Piper Sandler
Premium
The Fly
Inozyme downgraded to Neutral from Overweight at Piper Sandler
2M ago
INZY
Inozyme downgraded to Hold from Buy at Jefferies
Premium
The Fly
Inozyme downgraded to Hold from Buy at Jefferies
2M ago
INZY
Leerink bullish on BioMarin following Inozyme deal, expects additional BD
PremiumThe Fly
Leerink bullish on BioMarin following Inozyme deal, expects additional BD
2M ago
BMRN
INZY
Inozyme downgraded to Market Perform from Outperform at Raymond James
PremiumThe Fly
Inozyme downgraded to Market Perform from Outperform at Raymond James
2M ago
INZY
Inozyme downgraded to Hold from Buy at Needham
PremiumThe Fly
Inozyme downgraded to Hold from Buy at Needham
2M ago
INZY
Inozyme downgraded to Equal Weight from Overweight at Wells Fargo
PremiumThe Fly
Inozyme downgraded to Equal Weight from Overweight at Wells Fargo
2M ago
INZY
Inozyme Pharma’s INZ-701 Shows Promising Results in ENERGY-3 Study, Highlighting Investment Potential
PremiumRatingsInozyme Pharma’s INZ-701 Shows Promising Results in ENERGY-3 Study, Highlighting Investment Potential
2M ago
INZY
BioMarin says Inozyme deal to strengthen enzyme therapies portfolio
Premium
The Fly
BioMarin says Inozyme deal to strengthen enzyme therapies portfolio
2M ago
BMRN
INZY
Inozyme downgraded to Neutral from Outperform at Wedbush
Premium
The Fly
Inozyme downgraded to Neutral from Outperform at Wedbush
2M ago
INZY
Inozyme Pharma Merges with BioMarin for $270 Million
PremiumCompany Announcements
Inozyme Pharma Merges with BioMarin for $270 Million
2M ago
8K
INZY
BioMarin’s acquisition of Inozyme to strengthen enzyme therapies portfolio
PremiumThe Fly
BioMarin’s acquisition of Inozyme to strengthen enzyme therapies portfolio
2M ago
BMRN
INZY
BioMarin to acquire Inozyme for $4.00 per share in cash, or $270M
PremiumThe Fly
BioMarin to acquire Inozyme for $4.00 per share in cash, or $270M
2M ago
BMRN
INZY
Inozyme Pharma’s Strategic Focus and Promising Trial Data Earns Buy Rating
PremiumRatings
Inozyme Pharma’s Strategic Focus and Promising Trial Data Earns Buy Rating
2M ago
INZY
Inozyme reports Q1 EPS (44c) vs (38c) last year
PremiumThe FlyInozyme reports Q1 EPS (44c) vs (38c) last year
2M ago
INZY
Inozyme expects cash to fund operations into Q1 of 2026
Premium
The Fly
Inozyme expects cash to fund operations into Q1 of 2026
2M ago
INZY
INZY Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
INZY Earnings Report this Week: Is It a Buy, Ahead of Earnings?
3M ago
INZY

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >